This Article Full Text Full Text (PDF) Correction (v14,p3641) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Portera, C. C. Articles by Swain, S. M. PubMed PubMed Citation Articles by Portera, C. C. Articles by Swain, S. M.

Cardiac Toxicity and Efficacy of Trastuzumab Combined with Pertuzumab in Patients with Trastuzumab-Insensitive Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

Authors' Affiliations: ¹ Medical Oncology Branch, National Cancer Institute; ² Cardiovascular Branch, National Heart Lung and Blood Institute; ³ Diagnostic Radiology Department, Warren G. Magnuson Clinical Center; ⁴ Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute; ⁵ National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland; and ⁶ Washington Cancer Institute, Washington Hospital Center, Washington, District of Columbia

Requests for reprints: Sandra M. Swain, Washington Cancer Institute, Washington Hospital Center, 110 Irving Street Northwest, Washington, DC 20001. Phone: 202-877-8112; Fax: 202-877-8113; E-mail: Sandra.M.Swain{at}medstar.net.

Purpose: To evaluate safety and efficacy of trastuzumab with pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer who had progressive disease on trastuzumab-based therapy.

Experimental Design: Patients with measurable HER2⁺ metastatic breast cancer, 3 trastuzumab-based regimens, and left ventricular ejection fraction (LVEF) 55% received 8 or 6 mg/kg trastuzumab and 840 mg pertuzumab i.v. followed by 6 mg/kg trastuzumab and 420 mg pertuzumab every 3 weeks. Cardiac evaluation and tumor response were assessed every 3 and 6 weeks, respectively.

Results: Eleven patients received 64 cycles of trastuzumab plus pertuzumab. A total of 92 echocardiograms and 8 cardiac magnetic resonance imaging studies were done. With the lower limit of normal LVEF 55%, left ventricular systolic dysfunction was observed in six patients, three grade 1, two grade 2, and one grade 3 according to the National Cancer Institute Common Terminology Criteria for Adverse Events. The objective response rate was 18%. Two patients had partial responses, three had stable disease, and six had progressive disease. The median time to progression was 6 weeks. In baseline tumors from formalin-fixed paraffin-embedded primary and/or metastatic tumor biopsies, pHER2-Y1248 trended toward an increase in patients with partial response compared with those with stable disease/progressive disease (P = 0.095).

Conclusion: Trastuzumab plus pertuzumab may have clinical benefit in selected patients who have previously been treated with trastuzumab. Cardiac toxicity, although asymptomatic in most cases, was associated with this treatment. Further evaluation of efficacy of this combination is required to define the overall risks and benefits.